Medigen Biotechnology (3176) — Capital Reinvestment Ratio
Latest as of December 2024:
0.06x
Medigen Biotechnology (3176) has a Capital Reinvestment Ratio of 0.06x as of December 2024, meaning it reinvests 0% of its operating cash flow (NT$156.75 Million) in capital expenditures (NT$9.09 Million). See how much free cash does Medigen Biotechnology generate to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.06x
Capex / Operating Cash Flow
Operating Cash Flow
NT$156.75 Million
TWD
Capital Expenditures
NT$9.09 Million
TWD
Data as of
Dec 2024
Most recent filing
Medigen Biotechnology Capital Reinvestment Ratio (2003–2024)
This chart tracks Medigen Biotechnology's Capital Reinvestment Ratio across 5 annual periods.
Annual Capital Reinvestment Ratio for Medigen Biotechnology (2003–2024)
Year-by-year Capital Reinvestment Ratio for Medigen Biotechnology from 2003 to 2024. For live market cap and broader valuation context, see Medigen Biotechnology market capitalisation.
| Year | Reinvestment Ratio | Operating CF (TWD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 1.55x | NT$37.92 Million | NT$58.68 Million | ▲ +453.9% |
| 2021 | 0.28x | NT$517.45 Million | NT$144.55 Million | ▼ -84.1% |
| 2015 | 1.75x | NT$294.18 Million | NT$515.25 Million | ▲ +4303.1% |
| 2005 | 0.04x | NT$80.72 Million | NT$3.21 Million | ▲ +347.7% |
| 2003 | 0.01x | NT$445.46 Million | NT$3.96 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow